July 15, 2024
Gallbladder Cancer Market

Advancing Treatment Options To Drive Growth In The Gallbladder Cancer Market

Market Overview:
Gallbladder cancer is a rare type of cancer that forms in the gallbladder, a small organ located underneath the liver that stores and releases bile to aid in fat digestion. The most common symptoms of gallbladder cancer include abdominal pain, weight loss and jaundice. According to the American Cancer Society, approximately 12,320 new cases of gallbladder cancer are diagnosed each year in the United States, with it being three times more common in women than men. While surgical resection remains the main treatment option for early-stage disease, the prognosis is generally poor due to advanced stage at diagnosis. There is thus a growing demand for palliative chemotherapy regimens and targeted therapies that can help improve patient outcomes.

Market key trends:
One of the primary trends driving growth in the gallbladder cancer market is the launch of new targeted therapies. For instance, Lenvima (lenvatinib), developed by Eisai and Merck & Co., received FDA approval in 2021 for the treatment of patients with advanced gallbladder cancer who are first diagnosed with unresectable or metastatic disease. Clinical trials have demonstrated that Lenvima in combination with everolimus can prolong progression-free survival compared to placebo plus best supportive care. Another key launch was mirvetuximab soravtansine, an ADC therapy approved in 2021 under Priority Review by the FDA for patients with folate receptor alpha-positive metastatic gallbladder cancer previously treated with chemotherapy. These innovative targeted treatments are projected to significantly improve survival in this difficult-to-treat cancer type. Rising public-private research funding to develop better diagnostics and novel drugs for gallbladder cancer represents yet another emerging trend expected to boost the market growth over the forecast period.

The global Gallbladder Cancer Market Demand is estimated to be valued at US$ 73.6 Mn or Million in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Porter’s Analysis
Threat of new entrants: The Gallbladder Cancer market has low threat of new entrants due to high R&D costs and established brand loyalty of existing players.
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of alternative treatment options for gallbladder cancer.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to differentiated products and technologies required for treatment.
Threat of new substitutes: Threat of new substitutes is low as gallbladder cancer treatment has limited substitutes currently.
Competitive rivalry: High as major players compete on basis of new drug launches and technology advancements.

Key Takeaways
The global Gallbladder Cancer market is expected to witness high growth, exhibiting CAGR of 4.5% over the forecast period, due to increasing prevalence of gallbladder cancer and approvals of new drugs. The gallbladder cancer market size for 2023 is estimated to be US$ 73.6 Mn.

Regional analysis: North America is expected to dominate the global Gallbladder Cancer market owing to high healthcare expenditure and increasing incidence of gallbladder cancer in the US. However, Asia Pacific region is likely to exhibit highest growth rate during the forecast period due to growing patient population, rising awareness and improving healthcare infrastructure in countries like China and India.

Key players: Key players operating in the Gallbladder Cancer market are Eli Lilly and Company, Bristol-Myers Squibb, Roche, Pfizer, Novartis, Merck & Co., Inc., Sanofi, AstraZeneca, AbbVie, Gilead Sciences. These players are focused on introducing new drugs and combination therapies to strengthen their market position.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it